Pharmaids Pharmaceuticals (BSE: PHARMAID) is loss-making over the last 12 months, losing ₹4.56 Cr, so a P/E ratio does not apply. Its share price on 6 Nov 2026 was ₹28.57, 47% below its 52-week high. Debt is 0.49× equity. It is a small-cap company with a market cap of ₹101 Cr, ranked 119th of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 40% over the past year.
- ₹28.13
- ₹29.62
- ₹28.13
- ₹29.09
- 3.5K
Health check
- ReturnsBehind
−39.7% over a year, better than 0 of 7 peers.
- Price tagLoss-making
Earnings were negative over the last 12 months.
- Growthn/a
Not enough yearly results to measure.
- ProfitabilityNegative
ROCE -20.6% vs peer median 17.9%.
- Balance sheetStretched
Debt 0.49× equity, operating profit doesn’t cover interest, Piotroski 5 of 9.
- Red flags5 to check
Loss-making over the last twelve months.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹101 Cr
- Small cap
- P/E
- n/a
- Industry 28.7
- Price to book
- 2.13
- Peers 4.99
- Dividend yield
- 0.00%
- ROE
- −21.9%
- Peers 14.7%
- ROCE
- −20.6%
- Peers 17.9%
- Debt to equity
- 0.49
- Debt ₹23 Cr
- EPS (TTM)
- −₹1.28
- OPM (TTM)
- −35.2%
- Net margin −18.0%
- Sales growth
- −38.2%
- Latest quarter vs a year ago
- Profit growth
- n/a
- Year-ago quarter not reported
- Price to sales
- 3.98
- EV/EBITDA −14.1
Strengths and risks
Risks to check
- Loss-making over the last twelve months.
- Return on equity is low at −21.9%.
- Quarterly sales down 38.2% on a year ago.
- 47% below its 52-week high.
- Interest coverage of only −4.1×.
About Pharmaids Pharmaceuticals
Pharmaids Pharmaceuticals Limited, together with its subsidiaries, provides contract research and manufacturing services for pharma, biotech, agro, and chemical industries in India. It provides pharma intermediates, such as Dichloro Benzoyl nitrile, hydrazine carboximidamide 2 methane, pyridine carbonitrile, pyridine carboxylic acid, 8-chloro-10, 11-dihydro-4-aza-5H-dibenzo cycloheptene-5-one, 8-chloro-6,11-dihydro-11 cyclohepta pyridine,…
- Headquarters
- Bengaluru
- Employees
- 127
- Sector
- Healthcare
- ISIN
- INE117D01018
- Website
- pharmaids.com
Price range
- Avg volume (3M)
- 4.2K
- 1-year return
- minus 39.7%
- From 52-week high
- minus 47.0%
Peers · Drug Manufacturers - Specialty & Generic
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMASun Pharmaceutical Industries | 1,860.00 | plus 1.69% | 4,46,276 | 40.7 | 4.99 | 17.9% | 13.1% | 28.2% | 10.4% | 10.6% | 0.86% | plus 8.2% |
| DIVISLABDivi's Laboratories | 10,320.50 | plus 1.78% | 2,73,977 | 93.6 | 16.35 | 19.0% | 16.2% | 34.9% | 11.0% | 12.1% | 0.29% | plus 49.0% |
| TORNTPHARMTorrent Pharmaceuticals | 4,750.00 | plus 0.85% | 1,80,675 | 80.2 | 9.83 | 9.1% | 15.7% | 33.7% | 13.3% | 20.2% | 0.80% | plus 31.7% |
| LAURUSLABSLaurus Labs | 2,340.00 | minus 0.26% | 1,26,433 | 94.4 | 20.86 | 19.5% | 24.0% | 30.4% | 3.8% | 4.0% | 0.09% | plus 138.6% |
| ZYDUSLIFEZydus Lifesciences | 1,197.90 | plus 0.41% | 1,19,491 | 28.6 | 4.29 | 19.0% | 14.7% | 26.2% | 16.5% | 37.0% | 0.08% | plus 22.8% |
| DRREDDYDr. Reddy's Laboratories | 1,373.00 | plus 0.51% | 1,14,462 | 40.9 | 2.96 | 14.2% | 7.3% | 15.9% | 11.0% | −1.7% | 0.58% | plus 13.8% |
| CIPLACipla | 1,411.00 | plus 0.49% | 1,13,993 | 39.4 | 3.22 | 14.9% | 8.3% | 17.3% | 7.2% | 11.5% | 0.92% | minus 6.6% |
| PHARMAIDPharmaids Pharmaceuticals | 28.57 | minus 1.79% | 101 | – | 2.13 | −20.6% | −21.9% | −35.2% | – | – | 0.00% | minus 39.7% |
| Median of 7 peers | – | 0.51% | 1,26,433 | 40.9 | 4.99 | 17.9% | 14.7% | 28.2% | 11.0% | 11.5% | 0.58% | 22.8% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|
| 6.7 | 8.6 | 5.4 | 7.2 | 4.1 | |
| 12.1 | 13.9 | 7.9 | 7.5 | 4.9 | |
| −5.4 | −5.3 | −2.5 | −0.3 | −0.7 | |
| −81.2% | −61.9% | −46.1% | −4.7% | −18.1% | |
| 0 | 0.2 | 0.1 | 0.1 | 0 | |
| 1.2 | 1.1 | 0.7 | 0.6 | 0.6 | |
| 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | |
| 0 | 3 | −0.4 | −0.1 | 4.2 | |
| −7.2 | −3.7 | −4 | −1.5 | 2.4 | |
| 25.9% | 30.9% | 34.2% | 25.5% | 22.5% | |
| −5 | −2.5 | −2.5 | −1.8 | 2.2 | |
| -1.41 | -0.70 | -0.70 | -0.51 | 0.63 |
Profit & loss
- ROE
- −21.9%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| – | 15.1 | 18.8 | 27.4 | |
| – | – | +24.5% | +45.5% | |
| – | 27.4 | 31.5 | 40.9 | |
| −9.9 | −12.3 | −12.7 | −13.5 | |
| – | −81.5% | −67.6% | −49.3% | |
| −0 | 0.8 | −0 | 0 | |
| – | 1.6 | 2 | 3.3 | |
| 0 | 1.7 | 2.4 | 2 | |
| – | −0.8 | −0.1 | 2.5 | |
| −9.9 | −15.6 | −17.3 | −16.3 | |
| 23.7% | 24.2% | 21.8% | 29.0% | |
| −7.6 | −8 | −10.8 | −11.7 | |
| -5.86 | -3.56 | -3.05 | -3.31 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 21.4 | 35.3 | 35.3 | 35.3 | |
| 1 | 36.8 | 24.1 | 12.4 | |
| – | 8.5 | 39 | 23.4 | |
| 2.1 | 10.8 | 21.6 | 16.2 | |
| 24.6 | 91.3 | 120 | 87.3 | |
| 2.1 | 38.6 | 49.5 | 28.6 | |
| 2 | 7.1 | 4.9 | 6.1 | |
| – | 0.6 | 5.6 | 4 | |
| 16.1 | 4.8 | 2.1 | 2.8 | |
| 4.4 | 40.2 | 57.8 | 45.8 | |
| 24.6 | 91.3 | 120 | 87.3 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −4 | −10.6 | −15.1 | −4.1 | |
| −4.9 | −75 | −12.2 | 23.3 | |
| 21.3 | 77.7 | 23.4 | −20 | |
| 12.3 | −8 | −4 | −0.7 | |
| −1.7 | −22.9 | −12.5 | −4.5 | |
| −5.7 | −33.5 | −27.6 | −8.5 |
Shareholding pattern
This company is listed only on BSE, so there’s no NSE category split. See Major shareholders below for the named holders.
Major shareholders
Filings & events
News
No recent news coverage found.